Anavex Stock Price Crash: A Fault By Trial Design?

Anavex Life Sciences' unabashed self-promotion since late-2015 for its leading pipeline product ANAVEX 2-73, which is being studied as a treatment for Alzheimer's disease, may have been one reason the firm's stock crashed down this week following the presentation of Phase IIa data at the Alzheimer's Association International Conference. But the study with no control arm and only 32 patients for a neurological disorder also has some analysts questioning how robust the data are.